Loading...

Brilliant Violet 711™ anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6.7_BV711_061412
C57BL/6 mouse splenocytes were stained with CD3 PE and CD8a (clone 53-6.7) Brilliant Violet 711™.
  • 53-6.7_BV711_061412
    C57BL/6 mouse splenocytes were stained with CD3 PE and CD8a (clone 53-6.7) Brilliant Violet 711™.
Compare all formats See Brilliant Violet 711™ spectral data
Cat # Size Price Quantity Check Availability Save
100747 125 µL 168€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100759 50 µg 219€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100748 500 µL 348€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Li F, et al. 2022. Mediators Inflamm. 2022:5782922. PubMed
  2. Qi X, et al. 2022. FASEB J. 36:e22250. PubMed
  3. Klaus T, et al. 2022. JCI Insight. 7: . PubMed
  4. Cheng H, et al. 2023. Nat Metab. 5:314. PubMed
  5. Jerome JR, et al. 2023. Int J Mol Sci. 24: . PubMed
  6. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  7. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
  8. Bruand M, et al. 2021. Cell Reports. 36(3):109412. PubMed
  9. Hajnik RL, et al. 2022. Sci Transl Med. 14:eabq1945. PubMed
  10. Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed
  11. Lo WL, et al. 2023. Nat Immunol. 24:676. PubMed
  12. Tong L, et al. 2023. Sci Adv. 9:eade5041. PubMed
  13. Corria-Osorio J, et al. 2023. Nat Immunol. 24:869. PubMed
  14. Liu J, et al. 2023. Nat Commun. 14:2806. PubMed
  15. Effern M, et al. 2022. STAR Protoc. 3:101038. PubMed
  16. Aggen DH, et al. 2020. Clin Cancer Res. . PubMed
  17. Israelow B, et al. 2020. bioRxiv. . PubMed
  18. Miller CM, et al. 2020. J Virol. 94:00:00. PubMed
  19. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  20. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  21. Shapiro MR, et al. 2020. Front Immunol. 1.972222222. PubMed
  22. Yilmaz B, et al. 2021. Cell Host Microbe. 29(4):650-663.e9. PubMed
  23. Stathopoulou C, et al. 2020. Immunity. 49(2):247-263.e7.. PubMed
  24. Upadhyaya P, et al. 2021. J Immunother Cancer. 9:00. PubMed
  25. Wong E, et al. 2019. Cell Rep. 29:3047. PubMed
  26. Gawden‐Bone CM et al. 2018. Immunity. 49(3):427-437 . PubMed
  27. Chen JC et al. 2018. Cell systems. 7(1):92-103 . PubMed
  28. Tyagi AM et al. 2018. Immunity. 49(6):1116-1131 . PubMed
  29. Wiede F, et al. 2021. Cancer Discov. Online ahead of print. PubMed
  30. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  31. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  32. Esmaili S, et al. 2021. Cell Systems. 12(5):432-445.e7. PubMed
  33. Super M, et al. 2021. Nat Biomed Eng. Online ahead of print. PubMed
  34. Yu M, et al. 2021. J Clin Invest. 131:. PubMed
  35. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  36. Zhang H, et al. 2020. Cancer Cell. 37(1):37-54.e9.. PubMed
  37. Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed
  38. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  39. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  40. Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed
  41. Ramos CV, et al. 2020. Cell Reports. 32(3):107910. PubMed
  42. Pandey V, et al. 2021. eLife. 0.416666666666667. PubMed
  43. Crosse EI, et al. 2020. Cell Stem Cell. 27:822. PubMed
  44. Wang SS, et al. 2021. Biomedicines. 9:. PubMed
  45. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  46. Tyagi AM, et al. 2021. eLife. 10:00. PubMed
  47. Tang X, et al. 2022. Cell Rep. 41:111673. PubMed
  48. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  49. Campbell C et al. 2018. Immunity. 48(6):1245-1257 . PubMed
  50. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  51. Devi S, et al. 2021. Immunity. 54(6):1219-1230.e7. PubMed
  52. Sun T, et al. 2017. Mucosal Immunol. 0.954861111. PubMed
  53. Chen YG, et al. 2020. Molecular Cell. 76(1):96-109. PubMed
  54. Goh PK, et al. 2022. Sci Adv. 8:eabk3338. PubMed
  55. Zhang X, et al. 2020. Endocr Relat Cancer. 27:469. PubMed
  56. Holz LE et al. 2018. Cell reports. 25(1):68-79 . PubMed
  57. Zhang Y, et al. 2018. Nat Commun. 9:6. PubMed
  58. Ma K, et al. 2022. iScience. 25:104347. PubMed
  59. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  60. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  61. Cho S, et al. 2018. Nat Commun. 9:2757. PubMed
  62. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  63. Abdelfattah N, et al. 2022. Nat Commun. 13:767. PubMed
  64. Sjaastad FV, et al. 2020. Front Immunol. 11:1786. PubMed
  65. Williams JB, et al. 2020. Nat Commun. 0.876388889. PubMed
  66. Dangaj D, et al. 2019. Cancer Cell. 35:885. PubMed
  67. Lainé A, et al. 2021. Nat Commun. 12:6228. PubMed
  68. Wang X, et al. 2021. Cell. 184:5357. PubMed
  69. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  70. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  71. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  72. Glodde N et al. 2017. Immunity. 47(4):789-802 . PubMed
  73. Hayashida E, et al. 2019. J Neuroinflammation. 0.789583333. PubMed
  74. Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
  75. Rosen SF, et al. 2022. Genome Med. 14:108. PubMed
  76. Lee HN, et al. 2022. JCI Insight. 7:. PubMed
  77. Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed
  78. Yun JH, et al. 2021. JCI Insight. 6:. PubMed
  79. Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed
  80. Spath S, et al. 2022. iScience. 25:104998. PubMed
  81. Culina S, et al. 2015. Diabetes. 64: 3532 - 3542. PubMed
  82. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  83. Samuelson DR, et al. 2021. Commun Biol. 4:997. PubMed
  84. Effern M, et al. 2020. Immunity. 53(3):564-580.e9. PubMed
  85. Mitchell LA, et al. 2019. Oncotarget. 10:2252. PubMed
RRID
AB_2563510 (BioLegend Cat. No. 100747)
AB_2563510 (BioLegend Cat. No. 100759)
AB_2563510 (BioLegend Cat. No. 100748)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01.21.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account